Estimate of multiple myeloma patients by line of therapy in the USA: population-level projections 2020–2025
| Autor: | Gena Kanas, Katie Keeven, Knar Nersesyan, Cosmina Hogea, Otavio Clark, Leah Sansbury |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
End results Cancer Research Pediatrics medicine.medical_specialty Population level Line of therapy Medical Oncology Severity of Illness Index Systemic therapy 03 medical and health sciences 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols Epidemiology Prevalence medicine Humans Practice Patterns Physicians' Multiple myeloma Aged Retrospective Studies business.industry Incidence Incidence (epidemiology) Hematopoietic Stem Cell Transplantation Hematology General Medicine Middle Aged medicine.disease Progression-Free Survival United States Oncology 030220 oncology & carcinogenesis Female Registry data Multiple Myeloma business SEER Program 030215 immunology |
| Zdroj: | Future Oncology. 17:921-930 |
| ISSN: | 1744-8301 1479-6694 |
| Popis: | Aim: To report the results of a patient epidemiology model for multiple myeloma (MM) treatment by line of therapy (LOT) in the USA. Materials & methods: Surveillance, Epidemiology and End Results registry data and physician surveys were combined to project the incidence, prevalence and the number of MM patients treated with systemic therapy by LOT between 2020 and 2025. Results: Projected complete MM prevalence in the USA in 2020 was 144,922, increasing to 162,339 in 2025. Corresponding unique MM patients by LOT in 2020 were: 53,176 (1st; minimum–maximum: 47,304–59,212), 19,407 (2nd; 15,935–23,273), 6,481 (3rd; 5143–8877), 1649 (4th; 1146–2667) and 426 (5th; 217–876). Conclusion: MM incidence and prevalence by LOT is projected to continue to increase in the USA between 2020 and 2025. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|